AU2019276779A1 - Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody - Google Patents

Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody Download PDF

Info

Publication number
AU2019276779A1
AU2019276779A1 AU2019276779A AU2019276779A AU2019276779A1 AU 2019276779 A1 AU2019276779 A1 AU 2019276779A1 AU 2019276779 A AU2019276779 A AU 2019276779A AU 2019276779 A AU2019276779 A AU 2019276779A AU 2019276779 A1 AU2019276779 A1 AU 2019276779A1
Authority
AU
Australia
Prior art keywords
approximately
subject
antibody
pruritus
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019276779A
Other languages
English (en)
Inventor
Rohan GANDHI
Zamaneh MIKHAK
John PAOLINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiniksa Phamaceuticals Ltd
Original Assignee
Kiniksa Phamaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Phamaceuticals Ltd filed Critical Kiniksa Phamaceuticals Ltd
Publication of AU2019276779A1 publication Critical patent/AU2019276779A1/en
Priority to AU2026201985A priority Critical patent/AU2026201985A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019276779A 2018-04-25 2019-04-25 Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody Abandoned AU2019276779A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201985A AU2026201985A1 (en) 2018-04-25 2026-03-16 Treatment of skin diseases or disorders by delivery of anti-OSMRß antibody

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862662607P 2018-04-25 2018-04-25
US62/662,607 2018-04-25
US201862718324P 2018-08-13 2018-08-13
US62/718,324 2018-08-13
US201862765033P 2018-08-16 2018-08-16
US62/765,033 2018-08-16
US201862731618P 2018-09-14 2018-09-14
US62/731,618 2018-09-14
US201862757047P 2018-11-07 2018-11-07
US62/757,047 2018-11-07
US201862775350P 2018-12-04 2018-12-04
US62/775,350 2018-12-04
US201962789434P 2019-01-07 2019-01-07
US62/789,434 2019-01-07
US201962794356P 2019-01-18 2019-01-18
US62/794,356 2019-01-18
PCT/IB2019/000619 WO2019229525A2 (en) 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201985A Division AU2026201985A1 (en) 2018-04-25 2026-03-16 Treatment of skin diseases or disorders by delivery of anti-OSMRß antibody

Publications (1)

Publication Number Publication Date
AU2019276779A1 true AU2019276779A1 (en) 2020-12-10

Family

ID=68234020

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019276779A Abandoned AU2019276779A1 (en) 2018-04-25 2019-04-25 Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
AU2026201985A Pending AU2026201985A1 (en) 2018-04-25 2026-03-16 Treatment of skin diseases or disorders by delivery of anti-OSMRß antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201985A Pending AU2026201985A1 (en) 2018-04-25 2026-03-16 Treatment of skin diseases or disorders by delivery of anti-OSMRß antibody

Country Status (12)

Country Link
US (3) US20210054085A1 (https=)
EP (1) EP3784347A2 (https=)
JP (2) JP2021522241A (https=)
KR (2) KR102849806B1 (https=)
CN (2) CN121818914A (https=)
AU (2) AU2019276779A1 (https=)
BR (1) BR112020021739A2 (https=)
CA (1) CA3096582A1 (https=)
IL (1) IL326629A (https=)
MX (2) MX2020011172A (https=)
SG (1) SG11202010034WA (https=)
WO (1) WO2019229525A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI871349B (zh) * 2020-09-01 2025-02-01 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物
US20230391878A1 (en) * 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188500A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
JP6214010B2 (ja) * 2012-05-11 2017-10-18 公立大学法人和歌山県立医科大学 抗オンコスタチンｍ受容体ベータ抗体
SI3456743T1 (sl) * 2013-05-30 2022-01-31 Kiniksa Pharmaceuticals, Ltd. Proteini, ki vežejo antigen receptorja onkostatina M
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20170132143A (ko) * 2015-01-29 2017-12-01 옥스포드 유니버시티 이노베이션 리미티드 바이오마커
KR20170134748A (ko) * 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물

Also Published As

Publication number Publication date
EP3784347A2 (en) 2021-03-03
WO2019229525A2 (en) 2019-12-05
JP2024096933A (ja) 2024-07-17
CA3096582A1 (en) 2019-12-05
MX2020011172A (es) 2021-01-29
US20240101690A1 (en) 2024-03-28
IL326629A (en) 2026-04-01
CN121818914A (zh) 2026-04-10
WO2019229525A3 (en) 2020-03-19
CN112533675A (zh) 2021-03-19
US20210054085A1 (en) 2021-02-25
JP2021522241A (ja) 2021-08-30
MX2025006542A (es) 2025-07-01
US20250236676A1 (en) 2025-07-24
AU2026201985A1 (en) 2026-04-02
KR20250127348A (ko) 2025-08-26
KR20210018808A (ko) 2021-02-18
BR112020021739A2 (pt) 2021-01-26
KR102849806B1 (ko) 2025-08-22
SG11202010034WA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
US20240101690A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
Smolen et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Hoffman et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study
JP2021517566A (ja) 汎発性膿疱性乾癬の処置のための抗ｉｌ−３６ｒ抗体の使用
RU2714919C2 (ru) Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
JP2022126791A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
KR20090016707A (ko) Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
JP7495403B2 (ja) 巨細胞性動脈炎の治療
CA3080665A1 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
EP3687562B1 (en) Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein
WO2020036833A1 (en) Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
Fatima et al. Renal Manifestations in Juvenile Idiopathic Arthritis (JIA) And The Use Of Monoclonal Antibodies For Its Treatment: A Systematic Review
KR20260026080A (ko) 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
TW202515606A (zh) 用於治療及預防全身型膿疱性乾癬之方法
TW202532439A (zh) 治療氣喘之方法
WO2020096664A1 (en) Treatment for giant cell arteritis
HK40035543B (en) Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein
HK40035543A (en) Treatment of recurrent idiopathic pericarditis by delivery of interleukin-1 receptor antagonist fusion protein
Izumikawa et al. THU0474 Functional Analysis of Peripheral Blood Mononuclear Cells in a Fcas Patient with Novel NLRP3 Mutation
JP2008509989A (ja) 乾癬症の治療におけるｔｎｆ結合タンパク質−１